Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Multiple Myeloma 3Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 9Paclitaxel 9Doxorubicin 6Cyclophosphamide 6Carboplatin 5130-nm albumin-bound paclitaxel 5durvalumab 3yeast-CEA vaccine 2talazoparib 2sacituzumab govitecan 2olaparib 2glembatumumab vedotin 2avelumab 2Taxes 2Radiotherapy 2Leucovorin 2Fluorouracil 2Cisplatin 2Capecitabine 2Biopsy 2Albumin-Bound Paclitaxel 2ALT-803 2zimberelimab 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab duocarmazine 1tislelizumab 1taxane 1sabizabulin 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Triple Negative Breast Neoplasms × Leukapheresis × Clear all
NCT05539365 2025-01-29

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡